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Background—Rocky Mountain spotted fever (RMSF) is a disease that now causes significant 
morbidity and mortality on several American Indian reservations in Arizona. Although the disease 
is treatable, reported RMSF case fatality rates from this region are high (7%) compared to the rest 
of the nation (<1%), suggesting a need to identify clinical points for intervention.
Methods—The first 205 cases from this region were reviewed and fatal RMSF cases were 
compared to nonfatal cases to determine clinical risk factors for fatal outcome.
Results—Doxycycline was initiated significantly later in fatal cases (median, day 7) than 
nonfatal cases (median, day 3), although both groups of case patients presented for care early 
(median, day 2). Multiple factors increased the risk of doxycycline delay and fatal outcome, such 
as early symptoms of nausea and diarrhea, history of alcoholism or chronic lung disease, and 
abnormal laboratory results such as elevated liver aminotransferases. Rash, history of tick bite, 
thrombocytopenia, and hyponatremia were often absent at initial presentation.
Conclusions—Earlier treatment with doxycycline can decrease morbidity and mortality from 
RMSF in this region. Recognition of risk factors associated with doxycycline delay and fatal 
outcome, such as early gastrointestinal symptoms and a history of alcoholism or chronic lung 
disease, may be useful in guiding early treatment decisions. Healthcare providers should have a 
low threshold for initiating doxycycline whenever treating febrile or potentially septic patients 
from tribal lands in Arizona, even if an alternative diagnosis seems more likely and classic 
findings of RMSF are absent.
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Rocky Mountain spotted fever (RMSF), caused by the tick-borne bacterium Rickettsia 
rickettsii, can be a rapidly fatal disease even in previously healthy people. Before the 
discovery of effective antibiotics, reported fatality ranged from approximately 20% to 80% 
[1]. Doxycycline is the recommended treatment for suspected RMSF, regardless of patient 
age, and other commonly used broad-spectrum antibiotics are not effective in preventing 
death [2–4]. When doxycycline treatment is started in the first 5 days of symptoms, fatal 
outcome is unlikely; however, treatment efficacy decreases sharply after day 5 of symptoms 
[4–6].RMSF is difficult to diagnose during the first days of illness because presenting 
symptoms are nonspecific and diagnostic testing lacks sensitivity during this time [7]. 
Therefore, to prevent fatalities, clinicians must treat empirically as soon as the disease is 
suspected [2].
RMSF was reported sporadically in Arizona until an outbreak investigation in 2003 
identified a new vector for this disease in the United States, Rhipicephalus sanguineus [8]. 
Human cases were identified from as early as 2002 in one small community (community A), 
and molecular typing of the pathogen collected from human Arizona samples and R. 
sanguineus ticks confirmed R. rickettsii as the etiology of this outbreak [9, 10].
There have now been reports of cases from 6 tribal communities that have ecological 
conditions ranging from dry, hot desert to mountain pine forests [11]. The similarity 
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between affected communities is that all have free-roaming dogs with some degree of R. 
sanguineus infestation, as seen in the original investigation in community A [12].
Early, anecdotal reports from physicians in this region suggested differences in the 
epidemiology and clinical presentation of RMSF compared with other regions of the United 
States. An article published concurrently characterizes these differences, such as extended 
seasonality, younger age distribution, and lack of rash [13]. Another concerning difference 
was the high case fatality rate. Among 219 cases reported from tribal lands in Arizona from 
2003 to 2011, 16 died (7.3%) [14]; in contrast, the reported case fatality rate elsewhere in 
the United States was <1% [15]. Although there are multiple factors that may contribute to 
underestimation of the US case fatality rate, the number of fatalities seen each year from 
these 2 small communities was concerning. At the request of local healthcare providers and 
the first 2 Arizona tribal communities affected, we reviewed medical records of the first 205 
RMSF cases to assess risk factors for fatal outcome and identify clinical points of 
intervention to save lives.
METHODS
Data collection, healthcare facilities, and service populations have been described [13]. 
Approval for the study was obtained from participating tribes, the Indian Health Service, and 
the Centers for Disease Control and Prevention (CDC). The study was intended to prevent 
disease in response to an immediate public health threat and was therefore judged exempt by 
the CDC institutional review board on a nonresearch basis. The study was approved by the 
community A and B tribal councils through resolutions 11-2010-302 and AU-11-223, 
respectively. Cases included those diagnosed from 2002 through 30 September 2011. Case 
definitions and definitions of terms used in this manuscript are presented in the concurrent 
article by Traeger et al [13]. The following additional terms were used in this manuscript: 
Outpatient visit is a visit to the clinic or the emergency department, resulting in discharge 
home. Severe outcome includes any hospital admission (including intensive care unit [ICU] 
admission) or fatality. Late treatment is treatment with doxycycline initiated on day 5 of 
symptoms or later. A late symptom is a symptom that began on day 4 of illness or later. All 
diagnoses and causes of death were taken directly from the medical record.
Fatal cases were compared to nonfatal cases to identify risk factors for fatal outcome. 
Patients who received late treatment were compared to patients who were treated early 
(received doxycycline in the first 4 days of illness) to identify findings that may be risk 
factors for late treatment. If there was no information regarding a specific variable 
documented in the medical record, the case was not included in the analyses for that 
variable. Data were analyzed using EpiInfo [16]. Statistical differences in categorical 
variables were evaluated using the χ2 test; when the expected value of a cell was <5, Fisher 
exact test was used. Statistical differences in continuous variables were evaluated using 
analysis of variance or the Mann–Whitney/Wilcoxon 2-sample test when a nonparametric 
test was more appropriate. Statistical significance was set at α = .05.
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Among 205 cases of RMSF included in this analysis, 190 (93%) were nonfatal cases and 15 
(7%) were fatal cases (Table 1). Among cases, 85 were confirmed and 120 met the probable 
RMSF case definition. Fourteen fatal cases and 1 nonfatal case were confirmed by 
polymerase chain reaction (PCR) at the CDC. Additional sequencing was performed on a 
subset of these samples [9]. All case patients except 1 were identified as American Indians. 
The mean age of all case patients was 20 years, and mean age did not significantly differ 
between fatal and nonfatal cases. Children aged ≤10 years comprised 101 of 190 (53%) 
nonfatal cases and 7 of 15 (47%) fatal cases (Supplementary Figure 1). The median number 
of deaths per year during this time period was 1.7 and ranged from a low of 0 deaths in 2007 
to a high of 5 deaths in 2011.
The months with the highest proportion of fatal cases were April (25%), August (14%), and 
October (14%) (Supplementary Figure 2). Of the medical conditions collected, only a 
history of alcoholism (among adults) and chronic lung disease (CLD) were significant risk 
factors for fatal outcome, and only a history of alcoholism (risk ratio [RR], 1.84; 95% 
confidence interval [CI], 1.14–2.99) and CLD (RR, 2.88; 95% CI, 2.34–3.45) were 
significant risk factors for late treatment with doxycycline.
Symptoms
Fever (which included subjective reports) was the most common symptom (Table 2). All 
fatal cases included a fever during the course of illness, either subjective or measured. 
Whereas most of the symptoms that were more common in fatal cases occurred late in 
disease, gastrointestinal symptoms (abdominal pain, anorexia, nausea, vomiting, and 
diarrhea), hepatomegaly, splenomegaly, and peripheral edema typically began during the 
first 3 days of illness. Of the symptoms recorded, those significantly correlated with late 
treatment were headache (RR, 1.82; 95% CI, 1.10–3.02), nausea (RR, 1.72; 95% CI, 1.08–
2.75), diarrhea (RR, 1.66; 95% CI, 1.08–2.55), periorbital edema (RR, 2.61; 95% CI, 1.67–
4.07), dizziness (RR, 2.17; 95% CI, 1.22–3.84), and mental status change (RR, 2.66; 95% 
CI, 1.84–3.85). To provide a thorough clinical picture, frequencies of signs and symptoms 
were stratified by age (Supplementary Table 2B).
Rash occurred significantly later in fatal cases (median, day 5.5; range, 1–9) than in nonfatal 
cases (day 2; range, 1–14) (Table 3). Petechial rash was uncommon and late in disease 
course when present, occurring in 30 of 120 (15%) cases, on median day 7 of illness. A 
significantly higher proportion of fatal cases included a petechial rash with no evidence of 
prior maculopapular rash (6/12 [50%]) compared with 12 of 107 (11%) nonfatal cases in 
which the rash was described as petechial only.
Medical Care and Treatment
A median of 2 outpatient visits was recorded during both fatal and nonfatal cases, and both 
presented on day 2 of symptoms. However, the first notation of RMSF in the medical record 
occurred significantly later in fatal cases (median, day 7; range, 1–9) than nonfatal cases 
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(median, day 3; range, 1–14) (Table 3). The median day of symptoms that doxycycline was 
initiated was significantly later among fatal cases (day 7; range, 6–9) than nonfatal cases 
(day 3; range, 1–14). The median interval between the first notation of RMSF and initiation 
of doxycycline treatment was 0 days for both fatal and nonfatal cases.
None of the patients who died received doxycycline before day 6 of symptoms; however, 
most (52/62 [83.9%]) of the patients with documentation of late treatment survived. The 
following antibiotics were initiated within the first 3 days of symptom onset, but did not 
prevent death: ampicillin/sulbactam, ceftriaxone, clindamycin, cefazolin, gentamycin, 
vancomycin, imipenum, and amoxicillin. Azithromycin was administered to 2 case patients 
with confirmed RMSF, but mental status deterioration occurred in both and therapy was 
changed to doxycycline prior to day 6 of symptoms; both patients survived, but required 
ICU care for >7 days.
Laboratory Findings
Initial complete blood count, chemistry panel, and liver enzymes were performed later in 
fatal cases (Table 3). Abnormalities were more frequent in fatal cases for all laboratory 
results except gamma-glutamyl transpeptidase (Table 4). Laboratory abnormalities that were 
significantly correlated with late treatment with doxycycline included thrombocytopenia 
(RR, 1.98; 95% CI, 1.33–2.93), elevated AST (RR, 1.75; 95% CI, 1.10–2.78), elevated ALT 
(RR, 1.97; 95% CI, 1.31–2.95), and elevated total bilirubin (RR, 2.04; 95% CI, 1.35–3.09). 
An abnormal urine finding was more frequent in fatal than nonfatal cases (RR, 2.22; 95% 
CI, .66–7.40) (Supplementary Table 4B). There were 5 fatal cases and 17 nonfatal cases 
with ≥5 white blood cells in the first urine sample tested (RR, 2.22; 95% CI, .66–7.40).
Severe Outcomes
Eighty-six cases (42%) involved severe outcomes, including 15 fatalities and 71 
hospitalizations. Patients treated early were more likely to be managed as outpatients (Table 
5). However, the frequency of hospitalization and fatal outcome increased rapidly as the 
disease progressed without doxycycline treatment. There were 29 patients requiring 
admission to the ICU (Table 6). A majority of deaths (n = 13) occurred in the ICU, and 2 
occurred in the emergency department. The median day of symptoms that death occurred 
was day 9 (range, 6–20) (Table 3), and the most common causes of death listed in the 
medical record were sepsis (n = 9), disseminated intravascular coagulation (DIC; n = 7), 
multisystem organ failure (n = 5), and acute respiratory distress syndrome (ARDS; n = 3).
There were wide variations in the clinical presentations of the 15 fatal cases. Three patients 
were afebrile when temperature was measured at the first visit, and 2 of these patients (a 2-
year-old child and 39-year-old man) also had no history of subjective fever prior to 
presentation. The 39-year-old man did develop a measured fever after admission. However, 
the child had a subjective fever reported by the parent only and was afebrile whenever 
temperature was measured by the provider. Only 1 case patient who ultimately died was 
diagnosed with RMSF at the first visit, and treatment initiated at time of presentation on day 
7 was not effective at preventing death.
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This review of RMSF cases from 2 tribal communities in Arizona demonstrates the rapidly 
progressive nature of this disease and the need for early diagnosis and treatment. None of 
the fatal cases received early treatment with doxycycline. Treatment delay has often been 
linked to increased risk of fatal outcome [4–7, 17–19] and represents an important factor that 
is potentially modifiable in the clinical setting. Therefore, analysis was performed to 
determine which factors were associated with late treatment and may represent signals that 
should prompt early suspicion of the disease.
The prompt initiation of doxycycline treatment once RMSF was suspected in this patient 
cohort demonstrates that local providers are highly aware of appropriate antibiotic choice for 
RMSF. In this patient population, like others in the United States [6], patients with RMSF 
presented to healthcare providers early and returned multiple times. The first notation of 
RMSF in the medical records was late in fatal cases (median day 7), suggesting that the 
problem lies in the provider’s initial delay to include RMSF in the differential diagnosis for 
some patients. This case review identifies multiple factors that both complicate the initial 
presentation of RMSF and, at times, make another diagnosis appear more likely. 
Understanding of these factors may improve early recognition of RMSF and decrease 
morbidity and mortality from this disease.
Patients with a medical history of CLD or alcoholism were at greater risk of both receiving 
doxycycline late and dying of the disease. It is unclear if the small number of patients with 
CLD identified in this review represents a true significant risk factor; however, a history of 
alcoholism is likely to be significant. A higher risk of fatal outcome from other rickettsial 
diseases in patients with a history of alcoholism has been reported [20]. In this study, altered 
mental status, elevated aminotransferases, and low platelets were all found to be 
significantly correlated with late treatment, and the medical records suggested that providers 
sometimes attributed these signs and symptoms to complications of alcoholism in patients 
with this history. Altered mental status frequently occurs with alcohol intoxication, and 
elevated liver aminotransferases and low platelet counts are common sequelae of alcohol-
related liver disease. Also, patients with a history of alcoholism are at higher risk for other 
severe febrile illnesses, such as aspiration pneumonia, that may seem more likely than 
RMSF [21]. These factors, in addition to incomplete history of present illness provided by 
acutely intoxicated patients, may lead to delayed diagnosis, delayed treatment, and a higher 
risk of fatal outcome in these patients. Providers in the region should consider doxycycline 
early in febrile patients with a history of alcoholism, even if an alternative diagnosis seems 
more likely.
Other factors that may complicate presentation include abdominal symptoms, such as nausea 
and diarrhea, and abnormal urine findings. Abdominal pain is a symptom of RMSF that has 
led to misdiagnosis in other published reports [22, 23]. Diarrhea, often seen as an indicator 
of a benign process, such as viral gastroenteritis, was significantly correlated with late 
treatment and death in this study. Primary abdominal complaints led to 1 initial diagnosis of 
acute gastroenteritis and 2 diagnoses of nonspecific abdominal pain in fatal cases. In this 
review, the occurrence of abdominal pain, pyuria, and fever were initially diagnosed as 
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pyelonephritis and resulted in delayed diagnosis of RMSF and death in 2 patients. Even in 
the presence of abnormal urine findings or diarrhea, abdominal symptoms should be 
considered important early clinical triggers to initiate doxycycline in patients from this 
region.
While the factors described above may contribute to a complicated presentation of RMSF 
when present, there are additional factors that complicate by their absence. Rash appeared 
late in fatal cases (median, day 5.5 of symptoms), and this has been a documented risk factor 
for fatal outcome in other studies [24, 25]. In addition, although all fatal cases included 
fever, some patients were afebrile when temperature was measured at first presentation, and 
subjective reports of fever should not be discounted. Abnormal laboratory findings were 
more likely to be seen later as the disease progressed untreated. Relying on the presence of a 
rash, clinically measured fever, or laboratory abnormalities may lead to missed opportunities 
to begin treatment at the first visit.
This review is subject to several limitations. Patients with titers <1:128 or with enzyme-
linked immunosorbent assay testing alone are included in the national case definition for 
reporting, but were excluded from this analysis to improve the stringency of our findings. 
Furthermore, the higher case fatality rate seen in this region may be influenced by active 
testing of fatal cases through PCR confirmation at the CDC, a practice rarely pursued 
elsewhere [18, 26]. Thus, the rate calculated through national surveillance may be low due 
to national underreporting of fatalities and overinclusion of nonfatal cases that may not be 
true RMSF. Also, serologic testing lacks the specificity to differentiate between other 
spotted fever group rickettsia (SFGR); however, when PCR testing has been performed on 
samples from ill humans from these 2 communities, R. rickettsia has been the only SFGR 
detected. Finally, this study is a retrospective medical records review, and cases were 
managed and documented at the time of illness by physicians with no knowledge of this 
study, or that these records would be reviewed. The diagnoses and causes of death were 
taken from what the physician documented in the actual medical record, and the exact 
clinical criteria used to make diagnoses such as ARDS, DIC, renal failure, etc, might have 
varied between physicians.
Since the initial discovery of RMSF in this region, a high level of knowledge among 
providers has developed, as evidenced by high rates of doxycycline prescription among 
cases when RMSF is suspected; however, progress remains to be made. Improving early 
consideration of RMSF in patients with complicated presentations, such as those with 
history of alcoholism or signs and symptoms of another illness, and for those without classic 
signs and symptoms of RMSF, such as rash, will reduce mortality.
Changes in clinical practice should be encouraged through targeted provider education and 
healthcare facility oversight for local providers, and those at tertiary care facilities receiving 
transferred tribal patients, to ensure proper treatment is continued and confirmatory testing is 
completed. The treatment for RMSF, a short course of doxycycline, should be used even 
when the likelihood of RMSF seems low, to prevent fatalities similar to the ones that 
occurred in this population. The dose and duration of doxycycline used for RMSF have not 
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been shown to stain permanent teeth when given to pediatric patients [27], and doxycycline 
should be prescribed regardless of patient age based on clinical suspicion alone.
A clinical description of these RMSF case patients, with a comparison to patients who 
presented with similar febrile illnesses, is published concurrently [13]. Finally, public health 
interventions such as animal control, vector control, and veterinary care are essential to 
reduce overall incidence and mortality from RMSF. Cost analysis of medical care and loss 
of life and productivity caused by RMSF in this region may be helpful in illustrating that 
prevention measures are not only lifesaving, but cost effective.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 3
Day of Notable Clinical Events for Fatal and Nonfatal Cases of Rocky Mountain Spotted Fever in 2 Tribal 
Communities in Eastern Arizona
Event All Cases Nonfatal Fatal P Value
Day of symptoms of first doctor visit Day 2 (1–11) Day 2 (1–11) Day 2 (1–7)
Day of symptoms that RMSF was first mentioned in medical record Day 3 (1–14) Day 3 (1–14) Day 7 (1–9) .005
Day of symptoms that doxycycline was started Day 3 (1–14) Day 3 (1–14) Day 7 (6–9) .000
Duration between first mention and treatment 0 days (0–10) 0 days (0–10) 0 days (0–5) 
Day of symptoms hospitalization occurred Day 5 (1–11) Day 4 (1–11) Day 5 (1–9)
Day of symptoms first CBC was obtained Day 3 (1–14) Day 3 (1–14) Day 5.5 (1–9)  .008
Day of symptoms sodium was first tested Day 3 (1–12) Day 3 (1–12) Day 5 (1–9) .017
Day of symptoms AST was first tested Day 3 (1–14) Day 3 (1–14) Day 7 (1–9) .006
Day of symptoms that death occurred NA    NA      Day 9 (6–20)
Data are presented as median (range).
Abbreviations: AST, aspartate aminotransferase; CBC, complete blood count; NA, not applicable; RMSF, Rocky Mountain spotted fever.
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Table 5
Outcome by Day of Symptoms That Treatment With Doxycycline Was Started for First 9 Days of Symptoms 
for Confirmed Cases of Rocky Mountain Spotted Fever in 2 Tribal Communities in Eastern Arizona
Day of Symptoms Treatment Was Started (Total 
No. of Confirmed Patients Treated on That Day) Outpatient Hospitalized
Subset of Hospitalized
Subset of Hospitalized and 
ICU
ICU Fatal
Day 1 (6) 5 (83)   1 (17) 0 (0) 0 (0)
Day 2 (11) 8 (73)   3 (27) 0 (0) 0 (0)
Day 3 (9) 4 (44)   5 (56) 1 (11) 0 (0)
Day 4 (7) 3 (43)   4 (57) 1 (14) 0 (0)
Day 5 (8) 2 (25)   6 (75) 4 (50) 0 (0)
Day 6 (9) 0 (0)   9 (100) 5 (55) 3 (33)
Day 7 (11) 0 (0) 11 (100) 4 (36) 3 (27)
Day 8 (5) 1 (20)   4 (80) 2 (40) 2 (40)
Day 9 (4) 0 (0)   4 (100) 4 (100) 2 (50)
Data are presented as No. (%).
Abbreviation: ICU, intensive care unit.
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Table 6
Interventions and Notable Sequelae in Fatal and Nonfatal Cases of Rocky Mountain Spotted Fever in 2 Tribal 
Communities in Eastern Arizona
Intervention Nonfatal, No. (%) Fatal, No. (%) RR 95% CI
ICU admission 16/189 (8.5) 13/15 (86.7) 39.22   9.33–164.88
Plasma transfusion 4/186 (2.2)   9/13 (69.2) 32.19 11.44–90.62  
Platelet transfusion 5/186 (2.7) 10/12 (83.3) 61    14.69–253.38
PRBC transfusion 5/185 (2.7)   6/12 (50.0) 16.91 6.51–43.91
Whole blood transfusion 4/186 (2.2) 1/12 (8.3)   3.51   .55–22.20
Fluid boluses 77/186 (41.4) 14/14 (100) Undefined Undefined
Ventilation 6/189 (3.2) 15/15 (100) Undefined Undefined
Inotropic support 7/189 (3.7) 15/15 (100) Undefined Undefined
Immunoglobulins 0/184 (0)   1/12 (8.3) 17.73 9.98–31.47
ARDS 5/189 (2.6)   8/15 (53.3) 16.79 7.22–39.07
Respiratory failure 7/189 (3.7) 15/15 (100) Undefined Undefined
DIC 5/189 (2.6) 13/15 (86.7) 67.17 16.43–274.54
Multisystem organ failure 2/189 (1.1) 12/15 (80.0) 54.29 17.31–170.22
Renal insufficiency 7/189 (3.7) 10/14 (71.4) 27.35 9.59–78.00
Coma 2/188 (1.1) 9/15 (60) 26.18 11.36–60.37  
Digital necrosis 1/186 (0.5)   2/15 (13.3) 10.15 3.90–26.45
Abbreviations: ARDS, acute respiratory distress syndrome; CI, confidence interval; DIC, disseminated intravascular coagulation; ICU, intensive 
care unit; PRBC, packed red blood cell; RR, risk ratio.
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